FLT3 and leukemia: These results are in line with previous studies demonstrating that FT3-ITDMUT is subclonal and absent in the most immature AML-initiating/preleukemic cells, reinforcing that therapeutic targeting of subclonal mutations such as FLT3-ITDMUT might only have a transient clinical benefit in debulking the leukemia, but is unlikely to be curative, since it will not target the roots of the disease [48].